Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.

Popular Topics

  • Virtual and digital health
  • Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
  • Value-based healthcare 
  • Precision and stratified medicine
  • Integration of digital technology into existing workflow and procedures 
  • Next-generation immuno, cell, and gene therapies
  • Vaccines
  • Biomarkers, sequencing, and imaging
  • Rare diseases
  • MedTech and medical devices
  • Clinical trials
  • Addressing Social Determinants of Health
  • Treating chronic conditions like obesity and pain
  • Clinician and staff burnout

The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors. 

 

Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.

Empowered Patient Solutions

Feb 2, 2022

Amit Kumar is the President and CEO of Anixa Biosciences and is working on a prophylactic vaccine to prevent the onset of breast cancer rather than a therapeutic vaccine to fight the solid tumors. Anixa is also working on CAR-T therapy for solid tumors and using artificial intelligence and machine learning to discover compounds to treat COVID-19.

Amit elaborates, "We believe that trying to destroy cancer cells as they arise in a patient's body is much easier than waiting until that cancer becomes a large tumor mass with trillions of cells. As you know, cancer starts off with one single cell that becomes aberrant. Then it reproduces, it becomes two cells, four cells, eight cells, and so on, eventually becoming a tumor that is comprised of millions to trillions of cells. So if we try and destroy a tumor that's millions and trillions of cells, it's very difficult."

"You have a tumor microenvironment, you have a very immunosuppressive environment in that tumor, and it's very hard to address that tumor. However, if you could destroy those cells as they arise at the two-cell, four-cell, or handful-of-cell stage, then you could eliminate the tumor from ever arising. The cells never have a chance to become a tumor. That's what we're trying to do with our breast cancer vaccine."

"This is a therapeutic as opposed to a vaccine against coronavirus. We believe that the coronavirus is going to be an endemic disease, and there will always be a need for therapeutics. We want to be able to have a therapeutic that can be easily distributed, it's room-temperature-stable, unlike the vaccines, which require a cold chain, and something very inexpensive that can be taken by mouth."

@AnixaBio #CancerVaccine #CART #Immunotherapy #BreastCancer #COVID19 #COVIDTherapeutic

Anixa.com

Listen to the podcast here

Anixa